KIF18A Inhibitor Compounds With Lower Bone Marrow Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting KIF18A, such as Paclitaxel, are cytotoxic and have side effects like neutropenia and thrombocytopenia, necessitating the development of KIF18A inhibitors with improved selectivity and reduced toxicity.
Innovation Solution
Development of compounds that inhibit KIF18A, characterized by Formula I, which are designed to have low efflux, faster terminal half-life, and reduced cytotoxicity to bone marrow cells, thereby minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer drugs like Paclitaxel are used to target rapid cell division, then cell proliferation is inhibited, but cytotoxicity and side effects such as neutropenia and thrombocytopenia increase
Solution Approach 1:
The patent develops novel chemical compounds with modified molecular structures (Formula I) that change the pharmacological parameters of KIF18A inhibition. These structural modifications enable selective inhibition of cancer cell division while reducing off-target cytotoxic effects compared to traditional tubulin-targeting agents like Paclitaxel
Solution Approach 2:
The patent introduces KIF18A as a specific molecular target (intermediary) between the drug and the cell division process. By targeting this specific kinesin motor protein rather than tubulin directly, the compounds achieve more selective inhibition of mitosis in cancer cells, reducing harmful effects on normal cells
2Object-affected harmful factors
If KIF18A inhibitors are developed to improve selectivity, then side effects are reduced, but cellular efflux and pharmacokinetic properties may worsen
Solution Approach 1:
The patent systematically modifies chemical parameters of the inhibitor compounds (substituents R1-R6, ring structures) to optimize the balance between cellular efflux resistance and pharmacokinetic stability. The molecular structure in Formula I is designed to achieve appropriate lipophilicity and molecular weight for reduced efflux while maintaining stable plasma concentrations
Solution Approach 2:
The patent employs structure-activity relationship (SAR) analysis and pharmacokinetic feedback to iteratively optimize compound design. By measuring efflux ratios and pharmacokinetic parameters of initial compounds, the researchers refine the molecular structure to achieve the desired balance between selectivity and pharmacokinetic properties
3Reliability
If existing KIF18A inhibitors are used to treat cancer, then tumor growth is inhibited, but myelosuppression and thrombocytopenia occur
Solution Approach 1:
The patent designs compounds with localized structural features (specific substituent patterns on the core structure) that confer selective toxicity toward cancer cells while sparing bone marrow cells. The molecular structure is optimized to interact specifically with KIF18A in rapidly dividing cancer cells, reducing off-target effects on hematopoietic cells
Data Source
AI summary
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.